β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 6, 2014, Pages 1738-1743

  Smith, Jordan R ^a   Barber, Katie E ^a   Raut, Animesh ^a   Aboutaleb, Mostafa ^a   Sakoulas, George ^b,c   Rybak, Michael J ^a,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteria; Combination therapy; In vitro; Infection; Time kill

Indexed keywords

AMPICILLIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAROLINE; CEFTRIAXONE; DAPTOMYCIN; ERTAPENEM; BETA LACTAM;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; VANCOMYCIN RESISTANT ENTEROCOCCUS; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY;

BETA-LACTAMS; DAPTOMYCIN; DRUG SYNERGISM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84930509964     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv007     Document Type: Article

References (31)

1. Sievert DM, Ricks P, Edwards JR et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34: 1-14.
2. Rathnayake IU, Hargreaves M, Huygens F. Antibiotic resistance and virulence traits in clinical and environmental Enterococcus faecalis and Enterococcus faecium isolates. Syst Appl Microbiol 2012; 35: 326-33.
3. Hayakawa K, Marchaim D, Vidaillac C et al. Growing prevalence of vancomycin-resistant Enterococcus faecalis in the region with the highest prevalence of vancomycin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2011; 32: 922-4.
4. Billington EO, Phang SH, Gregson DB et al. Incidence, risk factors, and outcomes of Enterococcus spp. blood stream infections: a populationbased study. Int J Infect Dis 2014; 26: 76-82.
5. Carmeli Y, Eliopoulos G, Mozaffari E et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162: 2223-8.
6. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association:endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-434.
7. Casapao AM, Kullar R, Davis SL et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother 2013; 57: 4190-6.
8. Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 2013; 26: 759-80.
9. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001; 45: 454-9.
10. Hall AD, Steed ME, Arias CA et al. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2012; 56: 3174-80.
11. Kullar R, Casapao AM, Davis SL et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother 2013; 68: 2921-6.
12. Sader HS, Farrell DJ, Flamm RK et al. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). Int J Antimicrob Agents 2014; 43: 465-9.
13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI. Wayne, PA, USA, 2012.
14. Edelsberg J, Weycker D, Barron R et al. Prevalence of antibiotic resistance in US hospitals. Diagn Microbiol Infect Dis 2014; 78: 255-62.
15. Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013; 75: 304-7.
16. Munita JM, Panesso D, Diaz L et al. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 2012; 56: 4354-9.
17. Sakoulas G, Rose W, Nonejuie P et al. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2014; 58: 1494-500.
18. Hall Snyder A, Werth BJ, Barber KE et al. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. Antimicrob Agents Chemother 2014; 69: 2148-54.
19. Sakoulas G, Bayer AS, Pogliano J et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56: 838-44.
20. Sakoulas G, Nonejuie P, Nizet V et al. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother 2013; 57: 4042-5.
21. Sierra-Hoffman M, Iznaola O, Goodwin M et al. Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis. Antimicrob Agents Chemother 2012; 56: 6064.
22. Humphries RM, Kelesidis T, Tewhey R et al. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56: 6051-3.
23. Pogliano J, Osborne N, Sharp MD et al. A vital stain for studying membrane dynamics in bacteria: a novel mechanismcontrolling septation during Bacillus subtilis sporulation. Mol Microbiol 1999; 31: 1149-59.
24. Rice LB, Carias LL, Hutton-Thomas R et al. Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 2001; 45: 1480-6.
25. Henry X, Verlaine O, Amoroso A et al. Activity of ceftaroline against Enterococcus faecium PBP5. Antimicrob Agents Chemother 2013; 57: 6358-60.
26. Mainardi JL, Gutmann L, Acar JF et al. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother 1995; 39: 1984-7.
27. Fernandez-Hidalgo N, Almirante B, Gavalda J et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56: 1261-8.
28. Liao CH, Huang YT, Tsai HY et al. In vitro synergy of ampicillin with gentamicin, ceftriaxone and ciprofloxacin against Enterococcus faecalis. Int J Antimicrob Agents 2014; 44: 85-6.
29. Diaz L, Tran TT, Munita JM et al. Whole genome analyses of Enterococcus faecium with diverse daptomycin minimal inhibitory concentrations. Antimicrob Agents Chemother 2014; 58: 4527-34.
30. Tran TT, Panesso D, Mishra NN et al. Daptomycin-resistant Enterococcus faecalis diverts the antibiotic molecule from the division septum and remodels cell membrane phospholipids. mBio 2013; 4:e00281-13.
31. Odenholt I. Ertapenem: a new carbapenem. Expert Opin Investig Drugs 2001; 10: 1157-66.